Leif Gunnar Håkansson
Directeur Général chez CanImGuide Therapeutics AB
Profil
Leif Gunnar Håkansson is the founder of CanImGuide Therapeutics AB.
Prior to founding the company, he worked as the Head of Clinical Tumor Immunology Division at the University of Linköping and as an Associate Professor at the University of Lund.
He holds a doctorate degree from the University of Lund.
Postes actifs de Leif Gunnar Håkansson
Sociétés | Poste | Début |
---|---|---|
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Directeur Général | - |
Anciens postes connus de Leif Gunnar Håkansson
Sociétés | Poste | Fin |
---|---|---|
University of Linköping
University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services. | Corporate Officer/Principal | - |
University of Lund | Corporate Officer/Principal | - |
Formation de Leif Gunnar Håkansson
University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |